531 related articles for article (PubMed ID: 19948632)
1. The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus.
Meissner HC; Bocchini JA; Brady MT; Hall CB; Kimberlin DW; Pickering LK
Pediatrics; 2009 Dec; 124(6):1676-9. PubMed ID: 19948632
[No Abstract] [Full Text] [Related]
2. The 2009 COID recommendations for RSV prophylaxis: issues of efficacy, cost, and evidence-based medicine.
Krilov LR; Weiner LB; Yogev R; Fergie J; Katz BZ; Henrickson KJ; Welliver RC
Pediatrics; 2009 Dec; 124(6):1682-4. PubMed ID: 19948634
[No Abstract] [Full Text] [Related]
3. [Recommendations for immunologic prevention of respiratory syncytial virus (RSV) infections].
Z Geburtshilfe Neonatol; 1999 Dec; 203 Suppl 2():16. PubMed ID: 10612193
[No Abstract] [Full Text] [Related]
4. From the American Academy of Pediatrics: Policy statements--Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections.
Committee on Infectious Diseases
Pediatrics; 2009 Dec; 124(6):1694-701. PubMed ID: 19736258
[TBL] [Abstract][Full Text] [Related]
5. [Infections with RS viruses in children].
Krankenpfl J; 2004; 42(7-10):231. PubMed ID: 15675393
[No Abstract] [Full Text] [Related]
6. Cost-effectiveness of respiratory syncytial virus prophylaxis with palivizumab.
Mahadevia PJ; Malinoski FJ
Arch Pediatr Adolesc Med; 2007 May; 161(5):519-20; author reply 520. PubMed ID: 17485634
[No Abstract] [Full Text] [Related]
7. Annual variation in respiratory syncytial virus season and decisions regarding immunoprophylaxis with palivizumab.
Meissner HC; Anderson LJ; Pickering LK
Pediatrics; 2004 Oct; 114(4):1082-4. PubMed ID: 15466107
[No Abstract] [Full Text] [Related]
8. A health care management company's experience with palivizumab.
Silverman W
Manag Care; 2002 Jan; 11(1):45-6. PubMed ID: 11828875
[No Abstract] [Full Text] [Related]
9. [RSV-prophylaxis--to whom?].
Lossius K
Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2494. PubMed ID: 11070982
[No Abstract] [Full Text] [Related]
10. [Respiratory syncytial virus infections and preventive options].
Moll HA; de Groot R
Ned Tijdschr Geneeskd; 2000 Apr; 144(15):724-5. PubMed ID: 10778722
[No Abstract] [Full Text] [Related]
11. Small budget impact is a result of flawed assumptions and ignores questionable cost-effectiveness for RSV prophylaxis.
Hampp C; Kauf TL; Winterstein AG
Value Health; 2010 Aug; 13(5):684. PubMed ID: 20412545
[No Abstract] [Full Text] [Related]
12. Immunoprophylaxis of respiratory syncytial virus infection.
Simoes EA
Indian Pediatr; 2000 Mar; 37(3):243-7. PubMed ID: 10750065
[No Abstract] [Full Text] [Related]
13. [Polivizumab against respiratory syncytial virus?].
Brunvand L
Tidsskr Nor Laegeforen; 2000 Sep; 120(21):2570-2. PubMed ID: 11070999
[No Abstract] [Full Text] [Related]
14. Cost effectiveness of palivizumab in children with congenital heart disease in Germany.
Nuijten M; Lebmeier M; Wittenberg W
J Med Econ; 2009; 12(4):301-8. PubMed ID: 19811110
[TBL] [Abstract][Full Text] [Related]
15. [Prevention of respiratory syncytial virus infections with palivizumab].
Ellingsen BB; Aase SA; Øymar K
Tidsskr Nor Laegeforen; 2003 Apr; 123(7):941-3. PubMed ID: 12737068
[No Abstract] [Full Text] [Related]
16. [Prophylaxis against RS virus infection].
Navér L; Eriksson M; Ewald U; Linde A; Lindroth M; Schollin J
Lakartidningen; 2002 Jan; 99(3):170-1. PubMed ID: 11838073
[No Abstract] [Full Text] [Related]
17. A community health concern: respiratory syncytial virus and children.
Miller S
J Pediatr Nurs; 2010 Dec; 25(6):551-4. PubMed ID: 21035019
[TBL] [Abstract][Full Text] [Related]
18. Cost effectiveness of palivizumab for RSV prevention in high-risk children in the Netherlands.
Nuijten M; Lebmeier M; Wittenberg W
J Med Econ; 2009; 12(4):291-300. PubMed ID: 19811111
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of respiratory syncytial virus (RSV) risk factors and cost implications of immunoprophylaxis to infants 32 to 35 weeks gestation for health plans in the United States.
Krilov LR; Palazzi DL; Fernandes AW; Klein RW; Mahadevia PJ
Value Health; 2010; 13(1):77-86. PubMed ID: 19706010
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of palivizumab in premature infants without chronic lung disease.
Elhassan NO; Sorbero ME; Hall CB; Stevens TP; Dick AW
Arch Pediatr Adolesc Med; 2006 Oct; 160(10):1070-6. PubMed ID: 17018467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
